Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

他のバージョン（1件）を表示する

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

書誌詳細
主要な著者:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
フォーマット:	Journal article
言語:	English
出版事項:	2001

類似資料

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
著者:: Croucher, P, 等
出版事項: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
著者:: Croucher, P, 等
出版事項: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
著者:: Croucher, P, 等
出版事項: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
著者:: Croucher, P, 等
出版事項: (2002)

Osteoprotegerin and the development of myeloma bone disease
著者:: Croucher, P, 等
出版事項: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
著者:: Shipman, C, 等
出版事項: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
著者:: Vanderkerken, K, 等
出版事項: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
著者:: Shipman, C, 等
出版事項: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
著者:: Shipman, C, 等
出版事項: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
著者:: De Leenheer, E, 等
出版事項: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
著者:: Shipman, C, 等
出版事項: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
著者:: Croucher, P, 等
出版事項: (2003)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
著者:: Croucher, P, 等
出版事項: (2002)

Role of osteoprotegerin (OPG) in cancer.
著者:: Holen, I, 等
出版事項: (2006)

Bisphosphonates--mechanisms of action in multiple myeloma.
著者:: Shipman, C, 等
出版事項: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
著者:: Shipman, C, 等
出版事項: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
著者:: Shipman, C, 等
出版事項: (2000)

The role of osteoprotegerin in breast and prostate cancer
著者:: Holen, I, 等
出版事項: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
著者:: De Leenheer, E, 等
出版事項: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
著者:: Shipman, C, 等
出版事項: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
著者:: Shipman, C, 等
出版事項: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
著者:: Holen, I, 等
出版事項: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
著者:: Eaton, C, 等
出版事項: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
著者:: Anđelković Zlatibor, 等
出版事項: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
著者:: Huan Liu, 等
出版事項: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
著者:: Mueller, G, 等
出版事項: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
著者:: Mueller, G, 等
出版事項: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
著者:: Edwards, C, 等
出版事項: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
著者:: Holen, I, 等
出版事項: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
著者:: Eaton, C, 等
出版事項: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
著者:: Akshitha Devaraj, MBBS, 等
出版事項: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
著者:: Aiken Dao, 等
出版事項: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
著者:: Dongyeop Shin, 等
出版事項: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
著者:: Locklin, R, 等
出版事項: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
著者:: Waterman, E, 等
出版事項: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
著者:: Dongzheng Gai, 等
出版事項: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
著者:: Domingos Sousa, 等
出版事項: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
著者:: Dirk Hose, 等
出版事項: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
著者:: Lwin, S, 等
出版事項: (2017)